Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Crystal Jackson manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action. This action is assigned to 1 distinct examiner and is located within 1 distinct art unit. This indicates a singular focus for the current patent office interactions. For a practitioner, this means that the success of the current prosecution is tied to the specific perspectives of this 1 distinct examiner and the 1 distinct art unit involved.
The busiest examiner for this portfolio is DRISCOLL, MAUREEN VARINA, who is currently managing 1 busiest examiner pending action. Since the total number of pending office actions is 1, DRISCOLL, MAUREEN VARINA is the only examiner currently reviewing the company's Biotechnology & Pharmaceuticals innovations. The focus within 1 distinct art unit suggests a narrow technical application, and the practitioner must navigate the specific standards of that unit and the individual examiner to advance the 1 pending office action. This centralized prosecution structure simplifies communication but increases the impact of individual examiner tendencies on the overall portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DRISCOLL, MAUREEN VARINA | 1 | 64.9% | +41.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18698621 | MONOCONAL ANTIBODIES TO IL-25 AND USES THEREOF | DRISCOLL, MAUREEN VARINA | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18698621 | MONOCONAL ANTIBODIES TO IL-25 AND USES THEREOF | DRISCOLL, MAUREEN VARINA | 1644 | §112DP | Non-Final OA | — | Pending | Apr 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCrystal Jackson has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Maureen Varina Driscoll has the most, with 1 of Crystal Jackson's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
